Bioplastics Market Revenues to Reach a Volume of 3,951.43 kilotons by 2028 - Market Volume, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
14 juil. 2023 09h30 HE
|
Mordor Intelligence
Hyderabad, July 14, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Bioplastics Market Report (2023-2028)," the market volume is estimated at 1,783.16 kilotons in 2023. It...
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
09 août 2022 16h30 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
Q-Med Quarterly Report January - March 2003
12 mai 2003 10h15 HE
|
Q-Med
UPPSALA, Sweden, May 12, 2003 (PRIMEZONE) -- Q-Med:
Sales increased by 24 percent to SEK 141.3 (113.7) million. Adjusted for changes in exchange rates, sales increased by 33 percent.
On a rolling...
Actelion Announces Fourth Quarter and Full-year 2002 Financial Results Above Expectations
18 févr. 2003 01h54 HE
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Feb. 18, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today announced its financial results for the year 2002. With operating revenues more than...
Q-Med: Report on Operations 2002
10 févr. 2003 06h45 HE
|
Q-Med
UPPSALA, Sweden, Feb. 10, 2003 (PRIMEZONE) -- Q-Med (Stockholm:QMED):
-- Sales increased during the year by 36 percent to SEK 517.8 (380.2)
million. During the fourth quarter turnover...
Tripep: Preliminary Year-End Report for 2002
31 janv. 2003 03h52 HE
|
Tripep
HUDDINGE, Sweden, Jan. 31, 2003 (PRIMEZONE) -- Tripep AB (publ):
-- A new Board of Directors was elected at the extraordinary meeting of
shareholders held on September 17, 2002. The new...
Crucell Reports 2002 Annual Results
27 janv. 2003 02h29 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Jan. 27, 2003 (PRIMEZONE) -- Crucell N.V. (Nasdaq:CRXL) today announced its 2002 financial results. Total revenues for the year ended December 31, 2002 are $9.6 million...
GeneMedix plc: Quarter 3 Results for the Nine Months to August 31, 2002
19 nov. 2002 04h20 HE
|
GeneMedix plc
SUFFOLK, U.K., Nov. 19, 2002 (PRIMEZONE) -- GeneMedix plc (LSE:GMX) ("GeneMedix" or "the Company"), the U.K. generic biopharmaceutical company with operations in Europe and Asia and with joint London...
Innogenetics Reports Profitable Diagnostics Activities and Increased R&D Investments for the First Nine Months of 2002
15 nov. 2002 04h09 HE
|
Innogenetics
GENT, Belgium, Nov. 15, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its results for the first nine months ending September 30, 2002.
Highlights
-- Diagnostics Division...
Celsis International Plc: Interim Results for 6 Months to September 30, 2002
07 nov. 2002 08h08 HE
|
Celsis International Plc
SUFFOLK, U.K., Nov. 7, 2002 (PRIMEZONE) -- Celsis International plc ("Celsis") (Other OTC:CEITF) (LSE:CEL), a leading supplier of rapid microbial testing products and analytical laboratory services....